Total Payments
$100,617
2024 Payments
$24,174
Companies
8
Transactions
175
Payment Breakdown by Category
Education$34,432 (34.2%)
Other$31,161 (31.0%)
Consulting$17,417 (17.3%)
Travel$11,389 (11.3%)
Food & Beverage$4,892 (4.9%)
Research$1,326 (1.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Education | $34,432 | 49 | 34.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $29,661 | 14 | 29.5% |
| Consulting Fee | $17,417 | 8 | 17.3% |
| Travel and Lodging | $11,389 | 34 | 11.3% |
| Food and Beverage | $4,892 | 59 | 4.9% |
| Honoraria | $1,500 | 1 | 1.5% |
| Unspecified | $1,326 | 10 | 1.3% |
Payments by Type
General
$99,291
165 transactions
Research
$1,326
10 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| BioMarin Pharmaceutical Inc. | $83,068 | 132 | $0 (2024) |
| Travere Therapeutics, Inc. | $11,144 | 10 | $0 (2024) |
| PTC Therapeutics, Inc. | $3,066 | 4 | $0 (2024) |
| SANOFI US SERVICES INC. | $1,326 | 10 | $0 (2024) |
| GENZYME CORPORATION | $1,055 | 11 | $0 (2019) |
| Applied Therapeutics, inc. | $900.00 | 1 | $0 (2021) |
| Ultragenyx Pharmaceutical Inc. | $30.00 | 1 | $0 (2020) |
| Retrophin, Inc. | $28.26 | 6 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $24,174 | 29 | BioMarin Pharmaceutical Inc. ($17,123) |
| 2023 | $5,510 | 6 | Travere Therapeutics, Inc. ($5,450) |
| 2021 | $4,000 | 4 | PTC Therapeutics, Inc. ($2,975) |
| 2020 | $1,530 | 2 | BioMarin Pharmaceutical Inc. ($1,500) |
| 2019 | $19,372 | 67 | BioMarin Pharmaceutical Inc. ($18,288) |
| 2018 | $26,714 | 34 | BioMarin Pharmaceutical Inc. ($26,714) |
| 2017 | $19,317 | 33 | BioMarin Pharmaceutical Inc. ($19,317) |
All Payment Transactions
175 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | BioMarin Pharmaceutical Inc. | — | Consulting Fee | Cash or cash equivalent | $2,967.18 | General |
| 12/16/2024 | BioMarin Pharmaceutical Inc. | Palynziq (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,600.00 | General |
| Category: PKU | ||||||
| 07/29/2024 | BioMarin Pharmaceutical Inc. | Palynziq (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $200.00 | General |
| Category: PKU | ||||||
| 07/23/2024 | BioMarin Pharmaceutical Inc. | Palynziq (Drug) | Travel and Lodging | In-kind items and services | $197.00 | General |
| Category: PKU | ||||||
| 07/22/2024 | Travere Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $86.00 | General |
| 07/22/2024 | Travere Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $47.00 | General |
| 07/02/2024 | SANOFI US SERVICES INC. | — | — | Cash or cash equivalent | $72.00 | Research |
| Study: DFI-Phase 1/2 Dose ESC & EXP Study of SAR444836 (gene therapy) in Pts. w/Phenlyketonuria | ||||||
| 07/02/2024 | SANOFI US SERVICES INC. | — | — | Cash or cash equivalent | $31.61 | Research |
| Study: DFI-Phase 1/2 Dose ESC & EXP Study of SAR444836 (gene therapy) in Pts. w/Phenlyketonuria | ||||||
| 06/18/2024 | BioMarin Pharmaceutical Inc. | Palynziq (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $200.00 | General |
| Category: PKU | ||||||
| 06/18/2024 | BioMarin Pharmaceutical Inc. | Palynziq (Drug) | Food and Beverage | In-kind items and services | $78.00 | General |
| Category: PKU | ||||||
| 06/18/2024 | BioMarin Pharmaceutical Inc. | Palynziq (Drug) | Food and Beverage | In-kind items and services | $45.00 | General |
| Category: PKU | ||||||
| 06/17/2024 | BioMarin Pharmaceutical Inc. | Palynziq (Drug) | Food and Beverage | In-kind items and services | $78.87 | General |
| Category: PKU | ||||||
| 06/17/2024 | BioMarin Pharmaceutical Inc. | Palynziq (Drug) | Food and Beverage | In-kind items and services | $78.00 | General |
| Category: PKU | ||||||
| 06/12/2024 | SANOFI US SERVICES INC. | — | — | In-kind items and services | $479.40 | Research |
| Study: DFI-Phase 1/2 Dose ESC & EXP Study of SAR444836 (gene therapy) in Pts. w/Phenlyketonuria | ||||||
| 06/12/2024 | SANOFI US SERVICES INC. | — | — | In-kind items and services | $296.97 | Research |
| Study: DFI-Phase 1/2 Dose ESC & EXP Study of SAR444836 (gene therapy) in Pts. w/Phenlyketonuria | ||||||
| 06/12/2024 | SANOFI US SERVICES INC. | — | — | In-kind items and services | $213.57 | Research |
| Study: DFI-Phase 1/2 Dose ESC & EXP Study of SAR444836 (gene therapy) in Pts. w/Phenlyketonuria | ||||||
| 06/12/2024 | SANOFI US SERVICES INC. | — | — | In-kind items and services | $77.66 | Research |
| Study: DFI-Phase 1/2 Dose ESC & EXP Study of SAR444836 (gene therapy) in Pts. w/Phenlyketonuria | ||||||
| 06/12/2024 | SANOFI US SERVICES INC. | — | — | In-kind items and services | $62.71 | Research |
| Study: DFI-Phase 1/2 Dose ESC & EXP Study of SAR444836 (gene therapy) in Pts. w/Phenlyketonuria | ||||||
| 06/12/2024 | SANOFI US SERVICES INC. | — | — | In-kind items and services | $36.00 | Research |
| Study: DFI-Phase 1/2 Dose ESC & EXP Study of SAR444836 (gene therapy) in Pts. w/Phenlyketonuria | ||||||
| 06/12/2024 | SANOFI US SERVICES INC. | — | — | In-kind items and services | $28.00 | Research |
| Study: DFI-Phase 1/2 Dose ESC & EXP Study of SAR444836 (gene therapy) in Pts. w/Phenlyketonuria | ||||||
| 06/12/2024 | SANOFI US SERVICES INC. | — | — | In-kind items and services | $28.00 | Research |
| Study: DFI-Phase 1/2 Dose ESC & EXP Study of SAR444836 (gene therapy) in Pts. w/Phenlyketonuria | ||||||
| 06/11/2024 | Travere Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,750.00 | General |
| 06/07/2024 | BioMarin Pharmaceutical Inc. | Palynziq (Drug) | Travel and Lodging | In-kind items and services | $977.62 | General |
| Category: PKU | ||||||
| 05/24/2024 | BioMarin Pharmaceutical Inc. | Palynziq (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,800.00 | General |
| Category: PKU | ||||||
| 04/17/2024 | PTC Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $30.73 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| DFI-Phase 1/2 Dose ESC & EXP Study of SAR444836 (gene therapy) in Pts. w/Phenlyketonuria | SANOFI US SERVICES INC. | $1,326 | 10 |
About Dr. Janet Thomas, MD
Dr. Janet Thomas, MD is a Clinical Genetics (M.D.) healthcare provider based in Aurora, Colorado. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/25/2006. The National Provider Identifier (NPI) number assigned to this provider is 1225113954.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Janet Thomas, MD has received a total of $100,617 in payments from pharmaceutical and medical device companies, with $24,174 received in 2024. These payments were reported across 175 transactions from 8 companies. The most common payment nature is "Education" ($34,432).
Ad
Practice Information
- Specialty Clinical Genetics (M.D.)
- Location Aurora, CO
- Active Since 10/25/2006
- Last Updated 06/20/2024
- Taxonomy Code 207SG0201X
- Entity Type Individual
- NPI Number 1225113954
Products in Payments
- Kuvan (Drug) $41,577
- Palynziq (Drug) $25,009
- BMN 165 (Biological) $8,864
- Vimizim (Biological) $3,151
- NO PRODUCT DISCUSSED (Drug) $1,055
- DOJOLVI (Drug) $30.00
- (820) Cholbam (Drug) $28.26
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Clinical Genetics (M.D.) Doctors in Aurora
Matthew Taylor, Md, MD
Clinical Genetics (M.D.) — Payments: $54,563
Clinical Genetics (M.D.) $54,563
Shawn Mccandless, Md, MD
Clinical Genetics (M.D.) — Payments: $41,243
Clinical Genetics (M.D.) $41,243
Jessica Duis, M.d, M.D
Clinical Genetics (M.D.) — Payments: $26,043
Clinical Genetics (M.D.) $26,043
Aaina Kochhar, M.d, M.D
Clinical Genetics (M.D.) — Payments: $12,681
Clinical Genetics (M.D.) $12,681
Chun-Hui Tsai, Md, MD
Clinical Genetics (M.D.) — Payments: $5,956
Clinical Genetics (M.D.) $5,956
Dr. Farrah Rajabi, M.d, M.D
Clinical Genetics (M.D.) — Payments: $3,146
Clinical Genetics (M.D.) $3,146